Kymera Therapeutics (KYMR) PT Raised at Piper Sandler Following Positive BroADen Data
Tweet Send to a Friend
Piper Sandler analyst Edward Tenthoff raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $125.00 (from $98.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
